In Vitro Studies on Physiological and Chemical Stability of New LE404-Derivatives with Extended Half-Life

Abstract

Dibenzoazecines are a class of potential neuroleptics with high affinity to dopamine and serotonin receptors. The efficacy and high therapeutic range has already been demonstrated in vivo with the lead structure 7-methyl-5,6,7,8,9,14-hexahydrodibenzo[d,g]azecin-3-ol (LE404) and selected derivatives. There is a variety of new synthesized structurally different dibenzoazecine derivatives with the aim to improve pharmacokinetic parameters, all of which contain the lead structure LE404. For a multitude of these substances is still a lack of information, inclusive of stability, physicochemical parameters, pharmacokinetics and metabolism. Therefore, the present study investigated the stability properties of 17 new azecine derivatives, including esterase cleavage, stability in simulated gastrointestinal fluid, stability at different pH-values and determination of octanol/water-partition coefficients. These findings, in correlation to the properties and efficacy of the already in vivo tested substances, will be useful for safety and efficacy in further in vivo tests.

Key words

azecines - antipsychotic drugs - prodrugs - octanol/water-partition coefficients - esterase cleavage

• References

• 1 Witt T, Hock FJ, Lehmann J. 7-Methyl-6,7,8,9,14,15-hexahydro-5 H-benz[d]indolo[2,3- g]azecine: A new heterocyclic system and a new lead compound for dopamine receptor antagonists. J Med Chem 2000; 43: 2079-2081
• 2 Mohr P, Decker M, Enzensperger C. et al. Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist. J Med Chem 2006; 49: 2110-2116
• 3 Schulze M, Siol O, Robaa D. et al. Molecular combination of the dopamine and serotonin scaffolds yield in novel antipsychotic drug candidates – characterization by in vivo experiments. Drug Res 2012; 62: 252-260
• 4 Zergiebel S, Fleck C, Arndt HD. et al. Synthesis and Characterization of new Azecine-Derivatives as Potential Neuroleptics. Drug Res 2017; 67: 466-475
• 5 Zergiebel S, Arndt HD, Seeling A. Optimized synthesis of new LE404-derived azecine-prodrugs. Tetrahedron Lett 2017; 58: 3640-3642
• 6 ICH Guideline, I. Topic Q 2 B / Validation of Analytical Procedures: Methodology 1996; http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html12.07.2017
• 7 Europaean Pharmacopoeia 9.0, Deutscher Apotheker Verlag / Govi-Verlag-Pharmazeutischer Verlag GmbH (Eschborn), 2016
• 8 Robaa D, Eldin AbulAzm S, Lehmann J. et al. A novel non-phenolic dibenzazecine derivative with nanomolar affinities for dopamine receptors. Chem Biodivers 2011; 8: 431-439
• 9 Imai T. Human carboxylesterase isozymes: Catalytic properties and rational drug design. Drug Metab Pharmacokinet 2006; 21: 173-185
• 10 https://www.labunlimited.com/s/2685/4AJ-4004487/Macherey-Nagel-MN-Nucleodur-EC-C18-Isis-3 %C2 %B5m-125 × 4mm-760402.40 (23.08.2017)
• 11 OECD Guideline 117, OECD Guideline for testing of chemicals 1989; http://www.oecd.org/chemicalsafety/risk-assessment/1948169.pdf 07.08.2017
• 12 Lipinski CA, Lombardo F, Dominy BW. et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26
• 13 Elfgena A, Santiago-Schübel B, Gremera L. et al. Surprisingly high stability of the Aβ oligomer eliminating all-D-enantiomeric peptide D3 in media simulating the route of orally administered drugs. Eur J Pharm Sci 2017; 107: 203-207
• 14 MacDougall C, Guglielmo BJ. Pharmacokinetics of valaciclovir. J Antimicrob Chemother 2004; 53: 899-901
• 15 Bosak A, Gazić Smilović I, Sinko G. et al. isoproterenol, and their bisdimethylcarbamate derivatives as human cholinesterase inhibitors. J Med Chem 2012; 55: 6716-6723
• 16 Vaghela M, Sahu N, Kharkar P. et al. In vivo pharmacokinetic interaction by ethanolic extract of Gymnema sylvestre with CYP2C9 (Tolbutamide), CYP3A4 (Amlodipine) and CYP1A2 (Phenacetin) in rats. Chem Biol Interact 2017; 278: 141-151
• 17 Dhokchawle BV, Tauro SJ, Bhandari AB. Ester prodrugs of ketoprofen: Synthesis, hydrolysis kinetics and pharmacological evaluation. Drug Res 2016; 66: 46-50